课题基金 / 基金详情

BLOCKING HEPARANASE TRANSCRIPTION TO CONTROL METASTASIS

BLOCKING HEPARANASE TRANSCRIPTION TO CONTROL METASTASIS
阻断乙酰肝素酶转录以控制转移
批准号:
6141344
负责人:
HONG QI
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-03-01 至 2001-02-28

项目摘要

项目成果

HONG QI的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Heparanase is an endoglycosidase that degrades the heparan sulfate proteoglycan of the extracellular matrix by invading cells, notably metastatic tumor cells and migrating leukocytes. Transfection of the heparanase gene enhances the metastatic potential of rodent tumor cells, providing direct evidence for a role of heparanase in invasion. Heparanase inhibitors (mainly based on heparin and similar polysaccharides) have been shown to inhibit tumor growth or metastasis, angiogenesis and vascular damage in some cases in experimental models. Here, we propose to use recent advances in zinc finger DNA binding protein design to create novel transcription repressor proteins which are capable of repressing heparanase gene expression in vivo. Chimeric repressor proteins will be designed to bind to relevant target sites in the heparanase gene and repress heparanase transcription. We will determine the ability of the designed proteins to repress heparanase mRNA and protein expression in mammalian cells through transient transfection assays and the production of stable cell lines. Repression of heparanase transcription will be determined by measuring the level of reporter gene expression in the absence and presence of zinc finger binding protein. This innovative research will lead directly to the development of novel gene therapy approaches for metastatis cancer and potentially inflammatory diseases. PROPOSED COMMERCIAL APPLICATIONS: The success of this project will be a critical proof of principle for "designer repressor" technology. Designer DNA binding proteins and chimeric repressors comprise a new class of therapeutic drugs that potentially could be used to treat a large number of human diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SBIR PHASE II Point-of-Care HCV Detection
  • 批准号:
    10935701
  • 项目类别:
  • 资助金额:
    $150.0万
  • 财政年份:
    2023
  • 负责人:
    HONG QI
  • 依托单位:
Affinity Reagents for the Immune System of Golden Hamster (for SARS-CoV-2 induced long-COVID disease)
  • 批准号:
    10933277
  • 项目类别:
  • 资助金额:
    $60.0万
  • 财政年份:
    2023
  • 负责人:
    HONG QI
  • 依托单位:
SBIR TOPIC 107 AFFINITY REAGENTS FOR THE IMMUNE SYSTEM OF GOLDEN HAMSTER
  • 批准号:
    10688720
  • 项目类别:
  • 资助金额:
    $60.0万
  • 财政年份:
    2022
  • 负责人:
    HONG QI
  • 依托单位:
Rapid at-home Detection for Serologic Status of Hepatitis C Virus (HCV) Infection
  • 批准号:
    10709149
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2022
  • 负责人:
    HONG QI
  • 依托单位: